SERA PROGNOSTICS, INC.
Close on Oct 19, 2026
- Market cap
- $102.47M
- P/E (TTM)
- –
- Dividend yield
- –
About Sera Prognostics
Services-Medical Laboratories, SIC 8071
Sera Prognostics is a women’s health diagnostics company focused on improving maternal and neonatal outcomes through biomarker discovery. The company combines proteomics and bioinformatics platforms with clinical data to develop blood-based tests and predictive analytic tools. Its primary commercial product is the PreTRM test, a non-invasive blood test administered during weeks 18 through 20 of pregnancy to evaluate the risk of spontaneous preterm birth in women carrying a single fetus. The company's technology platform identifies dynamic protein changes to detect adverse pregnancy conditions.
The company serves expectant mothers, healthcare providers, and insurance payers seeking to assess pregnancy risks and reduce complications. Its proprietary biobank includes demographically and clinically annotated specimens collected from thousands of pregnant women across the United States, supplemented by international research collaborations in Europe, Asia, and Africa. Sera Prognostics is based in the United States and maintains its corporate headquarters in Salt Lake City, Utah.
Summary of the business section of Sera Prognostics's latest annual report, written by StockData.
Company profile
Company
- Legal name
- SERA PROGNOSTICS, INC.
- Headquarters
- Salt Lake City, UT
- Address
- 2749 E. Parleys Way, Suite 200 84109
- Phone
- (801) 990-0520
- Industry
- Services-Medical Laboratories
- Incorporated in
- Delaware
- Fiscal year ends
- December 31
- Auditor
- Ernst & Young LLP, Salt Lake City, Utah
Stock & identifiers
- Ticker
- SERA
- Exchange
- Nasdaq
- IPO date
- Jul 16, 2021
- Shares outstanding
- 39M, Aug 7, 2026
- Public float
- $82.90M, Jun 30, 2025
- Filer category
- <br>Emerging growth company
- SEC CIK
- 1534969
- CUSIP
- 81749D107
- ISIN
- US81749D1072
- EIN
- 26-1911522
Executives and directors
Officers and directors who filed ownership reports (Forms 3, 4, 5) in the last two years
| Name | Position | Shares owned |
|---|---|---|
| Zhenya Lindgardt | Chief Executive Officer, Director | 837,848 |
| Benjamin Jackson | General Counsel | 159,566 |
| Dyaarl Lee Anderson Jr. | Chief Commercial Officer | 76,198 |
| Tiffany Eul Davis Inglis | Chief Medical Officer | 91,589 |
| Austin Aerts | Chief Financial Officer | 301,190 |
| Scott Gleason | Chief Financial Officer | 117,924 |
| John J. Boniface | Chief Scientific Officer | 145,842 |
| Robert Gardner Harrison | Chief Information Officer | 76,712 |
| Paul Kearney | Chief Data Officer | 163,961 |
| Kim P. Kamdar | Director | 92,547 |
| Mark Christopher Capone | Director | 42,404 |
| Gregory C. Critchfield | Director | 1,477,718 |
| Sandra AJ Lawrence | Director | 38,899 |
| Joshua Phillips | Director | 81,691 |
| Jane F. Barlow | Director | 45,139 |
| Mansoor Raza Mirza | Director | 80,166 |
| Jeffrey Thomas Elliott | Director | 30,534 |
| Ryan Trimble | Director | 74,557 |
| Marcus Dean Wilson | Director | 7,117 |
Corporate history
Events identified from SEC filings
| Date | Event | Details |
|---|---|---|
| Jul 16, 2021 | IPO | Initial public offering priced (424B4 prospectus) |
| Jul 14, 2021 | Listing | Registration of securities on an exchange (Form 8-A) |